Journal article
What is a bad ALK? A scoping review of molecular markers of poor prognosis.
Abstract
e20530 Background: Patients with non-small cell lung cancer (NSCLC) with anaplastic lymphoma kinase ( ALK) rearrangements derive a significant and durable clinical benefit from tyrosine kinase inhibitors (TKI). However, a portion of patients have progressive disease as their best response and progress to death much earlier than expected which is termed primary resistance. This scoping review aims to summarize the known molecular mechanisms …
Authors
Chan SWS; Zeng J; Liu G; Jao K; Juergens RA
Journal
Journal of Clinical Oncology, Vol. 42, No. 16_suppl, pp. e20530–e20530
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
June 1, 2024
DOI
10.1200/jco.2024.42.16_suppl.e20530
ISSN
0732-183X